ISBN: 3-540-66476-9
TITLE: First International Moxifloxacin Symposium
AUTHOR: Mandell, L. (Ed.)
TOC:

Introduction to the Symposium 1
Lionel Mandell
PART 1  Antimicrobial Chemotherapy
Antimicrobial Chemotherapy  Today 7
John David Williams
Antimicrobial Chemotherapy  Tomorrow 12
Hartmut Lode
PART 2  Pre-clinical
Pre-clinical Microbiology  Streptococcus Pneumoniae 21
Regine Hakenbeck
Pre-clinical Microbiology  Gram-positive Cocci 27
Silvano Esposito
Pre-clinical Microbiology  Atypical Organisms 31
Ccile M. Bbar
Pre-clinical Microbiology  Summary I 36
Bernd Wiedemann
Pre-clinical Microbiology  Mycobacteria 37
Stephen H. Gillespie
In-vitro Activity of Moxifloxacin [Bay 12-8039], an 8-methoxy Quinolone, Compared to Other Fluoroquinolones Against Anaerobic Bacteria 43
Ellie Goldstein
Pre-clinical Microbiology  Fastidious Gram-negative Bacteria 49
Adolf Bauernfeind
Pre-clinical Microbiology  Respiratory Tract Infections
Susceptibility Survey  USA 54
Daniel Sahm
Pre-clinical Microbiology  Respiratory Tract Infections
Susceptibility Survey  Europe 59
David Felmingham
Pre-clinical Microbiology  Respiratory Tract Infections
Susceptibility Survey  Japan 67
Kazunori Tomono
Mechanisms of Fluoroquinolone Action and Resistance 75
Karl Drlica
Pre-clinical Microbiology  Summary II 84
Bernd Wiedemann
PART 3  Pharmacology
Pharmacokinetics and Pharmacodynamics of Antimicrobials 89
Richard Wise
Mini-Reviews  Pharmacokinetics/Pharmacodynamics (PK/PD) 94
Jerome J. Schentag
In vitro Models as Predictors of the Antimicrobial Effect of Moxifloxacin and Other Fluoroquinolones 98
Stephen Zinner
In vitro Models of Infection  Pharmacokinetic/Pharmacodynamic Correlates 104
Alasdair P. McGowan
Animal Model Experiences with Moxifloxacin 111
James M. Steckelberg
Current Thinking About Pharmacokinetics and Pharmacodynamics of Antimicrobials 118
John Turnidge
Pharmacology of Moxifloxacin  Absorption, Distribution, Metabolism and Excretion 122
Carl Erik Nord
Antimicrobial Drug-Drug Interations  Focus on Fluoroquinolones 127
Gary E. Stein
Pharmacology  Tissue Distribution 130
Ethan Rubinstein
Fluoroquinolones Phototoxicity  Moxifloxacin in Context 134
James Ferguson
Fluoroquinolone Safety and Tolerability 138
Peter Ball
PART 4  Clinical Needs in the Millenium
Clinical Needs in the Millenium  Community Acquired Pneumonia 147
Paul Lophonte
Clinical Needs in the Millenium  Pneumonia  The Role of Moxifloxacin 154
Martin Springsklee
Clinical Needs in the Millenium  Acute Exacerbations of Chronic Bronchitis 159
Robert Wilson
Clinical Needs in the Millenium  Acute Exacerbations of Chronic Bronchitis  The Role of Moxifloxacin 165
Deborah Church
Clinical Needs in the Millenium  Rhinosinusitis 170
Valerie J. Lund
Clinical Needs in the Millenium  Rhinosinusitis  The Role of Moxifloxacin 175
Barbara Hampel
Discussion on Clinical Needs in the Millenium 179
PART 5  Round Table Discussion
Round Table Discussion  Introduction 185
Round Table Discussion  Hospital Issues 186
Round Table Discussion  Community Issues 191
END
